JP Morgan Bonus Zert MRK 28.03.20.../ DE000JV102E1 /
15.01.2025 9:58:06 | Изменение-0.29 | Бид13:31:27 | Предложение13:31:27 | Базовый актив | Цена исполнения | Дата истечения | Тип опциона |
---|---|---|---|---|---|---|---|
179.43EUR | -0.16% | 179.51 Величина цены спроса: 3,000 |
179.61 Величина цены предложения: 3,000 |
MERCK KGAA O.N. | - EUR | 28.03.2025 | Call |
GlobeNewswire
03.06.2024
Biolojic Design Enters into a Multi-Target Drug Discovery Collaboration with Merck KGaA, Darmstadt, ...
GlobeNewswire
29.05.2024
Jeito Capital announces the acquisition by Merck & Co (NYSE: MRK) of its portfolio company EyeBio fo...
GlobeNewswire
29.05.2024
Anaveon announces IND approval of ANV600-001 (EXPAND) Phase I/II clinical study
GlobeNewswire
07.05.2024
CytomX Therapeutics Announces Clinical Collaboration with Merck to Evaluate CX-801 in Combination wi...
GlobeNewswire
06.05.2024
Press Release Biocartis NV: Biocartis and Merck to Collaborate on Improving Patient Access to Person...
GlobeNewswire
04.03.2024
C4 Therapeutics Announces Strategic Discovery Research Collaboration with Merck KGaA, Darmstadt, Ger...
GlobeNewswire
21.12.2023
Arch Biopartners Receives Approval from Ethics Committee in Turkey to Proceed with Phase II Cardiac ...
GlobeNewswire
14.12.2023
ITM Executes License Agreement to Obtain Worldwide Exclusive License for the Clinical Development an...
GlobeNewswire
17.10.2023
ImmunOs Therapeutics Announces Clinical Trial Collaboration with Merck & Co., Inc., Rahway, NJ, USA
- Первая страница
- Назад
- 1
- 2
- 3
- 4
- Следующий
- Последняя страница